MetaCap

Bicycle Therapeutics plc ADR (BCYC)

NASDAQ: BCYCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

2.90-0.15 (-4.92%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BCYC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$203.27M
EPS (TTM)
-$2.03
52-week range
2.85 – 7.83
Day range
2.85 – 3.00
Volume / Avg
1.02M / 444.72K
Beta
—

52-week range

$2.85$7.83

BCYC stock today

On Nov 20, BCYC ended the session at $2.90, shedding $0.15 (4.92%), versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 1.02M shares, a sign of unusually heavy trading. Shares are 63.0% below their 52-week high of $7.83, set on Nov 28, 2025 and 1.8% above the 52-week low of $2.85, near the bottom of the past year's range.

BCYC is down 59.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 54.1%. Bicycle Therapeutics has posted a net loss over the last twelve months (EPS of -$2.03), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Bicycle Therapeutics

Company profile

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Kevin Lee M.B.A., Ph.D.
Headquarters
Cambridge
Employees
288
IPO year
2019

Financial highlights

Full financials

In fiscal 2025, Bicycle Therapeutics generated $72.6 million in revenue, up 105.8% from fiscal 2024, its 5th consecutive year of revenue growth. Bicycle Therapeutics reported a net loss of $219.0 million, compared with a loss of $169.0 million a year earlier. Operating margin was -340.4%.

Bicycle Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$72.59M$35.27M$26.98M$14.46M$11.70M
Growth+105.77%+30.76%+86.52%+23.65%+12.58%
Net income$-218.96M$-169.03M$-180.66M$-112.72M$-66.82M
EPS (diluted)$-3.16$-2.90$-5.08$-3.80$-2.67

Analyst forecast

Forecast

Consensus (9 analysts)

buy

Avg. price target

$9.17+216.21%

  • Strong buy 2
  • Buy 4
  • Hold 3
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $14.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$-0.15 vs $-0.30
Surprise
+50.00%

BCYC news

All BCYC news

Bicycle Therapeutics peers

Health Care sector
BCYC peer companies
CompanyPrice% ChgMarket capCompare
FTHFaeth Therapeutics Inc.7.88-9.32%$203.65Mvs BCYC
DRUGBright Minds Biosciences Inc.20.40-1.45%$201.23Mvs BCYC
NGENNervGen Pharma Corp.1.85-3.91%$198.55Mvs BCYC
VNDAVanda Pharmaceuticals Inc.3.45-6.13%$208.32Mvs BCYC
BIOABioAge Labs Inc.4.28-9.13%$196.67Mvs BCYC
YARWYarrow Bioscience Inc.12.90-9.35%$196.53Mvs BCYC
CYPHCypherpunk Technologies Inc.1.41-18.02%$210.15Mvs BCYC
ACIUAC Immune SA1.95-8.45%$193.88Mvs BCYC

Indexes, lists and sector

Bicycle Therapeutics stock FAQ

What is Bicycle Therapeutics's stock price today?

BCYC last traded at $2.90 as of Nov 20, 4:00 PM EST, down 4.92% on the day. Prices are delayed at least 15 minutes.

Who is Bicycle Therapeutics's CEO?

Dr. Kevin Lee M.B.A., Ph.D. is the chief executive officer of Bicycle Therapeutics plc ADR, which has about 288 employees.

What is the BCYC 52-week high?

The 52-week high for BCYC is $7.83 and the 52-week low is $2.85. The stock is currently 63.0% below its high.

Compare BCYC